HC Wainwright Reaffirms “Buy” Rating for Kymera Therapeutics (NASDAQ:KYMR)
HC Wainwright reiterated their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research note issued to investors on Monday, Benzinga reports. The firm currently has a $46.00 price target on the stock. A number of other equities analysts have also recently weighed in on KYMR. Stifel Nicolaus increased their price […]
More Stories
Trump Arrives in Beijing for High-Stakes Summit Amid Taiwan, Iran Tensions
By Michael Zhuang President Donald Trump landed in Beijing on May 13 for his first trip to China in nearly...
US Rents Fall for 33rd Straight Month as Multifamily Construction Surges
By Mary Prenon U.S. renters may continue to save money as the national median asking rent fell for the 33rd...
Iran Hasn’t Exported Crude Oil in 28 Days Amid US Blockade: Maritime Intelligence Company
By Victoria Friedman The Iranian regime has not been able to export any crude oil for nearly a month amid...
CIA Analysts Believed COVID-19 Came From Lab, Leaders Buried Assessments: Whistleblower
By Zachary Stieber CIA experts believed COVID-19 likely came from a laboratory in China, but leaders in the agency changed...
EBay Turns Down GameStop’s $55.5 Billion Takeover Proposal
By Andrew Moran EBay has turned down videogame retailer GameStop’s $55.5 billion takeover proposal. The online marketplace, in a May...
Trump Nominates Lake, Mastriano to Diplomatic Posts
By Kimberly Hayek President Donald Trump on Monday announced a slew of nominations sent to the U.S. Senate, including two...